Multiple Myeloma Posts - Page 2 of 26 on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Posted by on Dec 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) therapy for patients with newly diagnosed multiple myeloma (MM). The data showed that adding daratumumab to the lenalidomide and dexamethasone (Rd) regimen was safe and improved...

Read More

Effect of maintenance therapy after second AHCT in patients with multiple myeloma.

Effect of maintenance therapy after second AHCT in patients with multiple myeloma.

Posted by on Dec 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study explored the role of maintenance therapy after a second autologous hematopoietic cell transplant (AHCT2) in patients with multiple myeloma (MM). The data showed that maintenance therapy after AHCT2 was associated with better outcomes in these patients. Some background MM is commonly hard-to-treat. Many patients are treated...

Read More

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Posted by on Nov 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro) as maintenance therapy after bortezomib (Velcade)-based induction therapy in real-world patients with multiple myeloma (MM). The data showed that the outcomes of these patients in the real-world setting were good with manageable side effects. Some background...

Read More

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Posted by on Nov 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of daratumumab (Darzalex) as maintenance therapy following autologous stem-cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). The data showed that maintenance therapy with daratumumab resulted in significant improvements in outcomes compared to observation only in patients that...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Can pomalidomide improve multiple myeloma treatment?

Can pomalidomide improve multiple myeloma treatment?

Posted by on Oct 17, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study looked at pomalidomide (Pomalyst) for patients with multiple myeloma (MM) which had returned after previous treatment. It found that adding pomalidomide to Vd (bortezomib, dexamethasone) led to better outcomes than Vd alone. Some background MM is a blood cancer in adults. Myeloma cells are cancerous versions of plasma cells,...

Read More

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Posted by on Oct 9, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of teclistamab (JNJ-64007957) for patients with recurrent or unresponsive multiple myeloma (MM). This study concluded that this treatment was safe and showed promising effectiveness for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can...

Read More

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

Posted by on Sep 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...

Read More

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Posted by on Sep 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...

Read More

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Posted by on Sep 12, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...

Read More